OTTAWA, April 11, 2014 /CNW/ -
The issue: Four unauthorized drugs being sold at two SVN FUEL stores - one in
Burnaby and one in Coquitlam, B.C. - were seized by Health Canada as
they contain ingredients that are potentially dangerous to the health
The products, and the unapproved ingredients they contain, include
Jack3d (DMAA (1, 3-dimethylamylamine), Red Rockets (ephedrine and
caffeine), West Pharm Therma Lean (ephedrine and caffeine), and
OxyElite Pro (1, 3-dimethylamylamine HCl and Yohimbe Bark extract).
They were being promoted for weight management.
Who is affected: Canadians who have used or purchased any of these products.
What consumers should do:
Speak to a healthcare professional if you have taken any of the products
and have concerns regarding your health.
Read the label of the products you buy to verify that they have been
assessed by Health Canada for safety, effectiveness and quality. Health
products that have been authorized for sale by Health Canada will have
an eight-digit Drug Identification Number (DIN), a Homeopathic Medicine
Number (DIN-HM) or a Natural Product Number (NPN) on the label.
Report any adverse events associated with the use of these products to Health Canada.
What Health Canada is doing:
Health Canada seized Jack3d from SVN FUEL, Unit 102, 9952 Lougheed Hwy.
Red Rockets, West Pharm Therma Lean and OxyElite Pro were seized from
SVN FUEL, Unit 138, 3000 Lougheed Hwy, Coquitlam, B.C.
Health Canada previously advised Canadians of a U.S. Food and Drug Administration (FDA) warning not to use dietary supplements labelled as "OxyElite Pro" following
several U.S. reports of serious liver injury.
Jack3d was found to contain DMAA (dimethylamylamine), a drug that is not
authorized for use in Canada. Side effects include high blood pressure,
shortness of breath, chest pain, stroke and psychiatric disorders.
Red Rockets and West Pharm Therma Lean were found to contain ephedrine and caffeine. Ephedrine and caffeine,
when combined together, may cause serious and possibly fatal adverse
effects ranging from dizziness, tremors, headaches and irregularities
in heart rate, to seizures, psychosis, heart attacks and stroke.
Canadians suffering from heart conditions, high blood pressure and
diabetes are among those particularly at risk. Ephedrine is authorized
for the relief of nasal congestion but is not authorized for sale in
Canada as a stimulant or weight management product.
In addition to dimethylamylamine, OxyElite Pro was found to contain Yohimbe bark extract. The use of any unauthorized
drugs containing yohimbine (either as yohimbine hydrochloride or
yohimbe bark extract) may result in serious adverse reactions,
particularly in people with high blood pressure, heart, kidney or liver
disease. Side effects associated with yohimbine include increased blood
pressure and heart rate, anxiety, dizziness, tremors, headache, nausea
and sleep disorders. It should not be used by children, pregnant or
In 2010, Health Canada received four reports of adverse reactions
associated with the use of West Pharm Therma Lean.
For more information:
Consumers and health professionals wanting more information about this
advisory from Health Canada can contact the Public Enquiries Line at
613-957-2991, or toll free at 1-866-225-0709.
Media enquiries related to this Advisory should be directed to Health
Canada Media Relations at 613-957-2983.
1. Jack3d (contains DMAA (1,3-dimethylamylamine)
2. Red Rockets (contains Ma Huang, 8% Ephedrine and caffeine)
3. West Pharm Therma Lean (contains Ma Huang, 8% Ephedrine and caffeine)
4. OxyElite Pro (contains 1, 3-dimethylamylamine HCl and Yohimbe Bark
How to report side effects of health products to Health Canada:
Call toll-free at 1-866-234-2345
Visit MedEffect Canada's web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax.
Related Health Canada Content:
Stay connected with Health Canada and receive the latest advisories and
product recalls using social media tools.
PDF available at: http://stream1.newswire.ca/media/2014/04/11/20140411_C9594_DOC_EN_39171.pdf
SOURCE: Health Canada
For further information:
Également disponible en français